Delaware biotech startups: source STAR Campus, not the registry

A database filtered on biotech plus Delaware returns several hundred companies. The state holds more than 2.1 million active legal entities and roughly 11,000 life sciences employees.

Delaware biotech startups that a corporate acquirer can actually work are found on physical-presence rosters, not in a state-domicile filter. Four inputs are worth screening: the STAR Campus Resident Directory in Newark, the Delaware Technology Park incubator on that campus (DTP@STAR), The Innovation Space at the former DuPont Experimental Station in Wilmington, and the project rosters of NIIMBL, the federal biopharmaceutical manufacturing institute headquartered on STAR.

A Delaware state filter is an anti-signal, not a weak signal

Filtering on Delaware as a location actively degrades a target list, because incorporation there is a legal default rather than a statement about operations. The Delaware Division of Corporations reports that about 66.7% of Fortune 500 companies are incorporated in the state, that 81.4% of US-based IPOs in 2024 chose it as their corporate home, and that more than 2.1 million legal entities are active there. Almost all of them do their work somewhere else.

A data vendor's "headquarters: Delaware" field is frequently a registered agent's address on North Orange Street, shared with thousands of other filings. A company with wet labs in Newark and a shell holding entity for a Singapore operating company look identical in that column. Start by deleting the state field, then require a street address attached to a building where somebody runs an experiment.

Newark holds the labs, Wilmington holds the accelerator

The two sites that get conflated in writeups of this ecosystem sit about 13 miles apart. The STAR Campus is 272 acres of University of Delaware land in Newark, and its resident directory lists both NIIMBL, in the Ammon Pinizzotto Biopharmaceutical Innovation Center, and DTP@STAR, the Delaware Technology Park incubator. The Innovation Space is not there. It occupies the former DuPont Experimental Station in Wilmington, and its Science Inc. accelerator has supported 88 startups from 20 states and five countries, with the surrounding ecosystem raising $1.24B since 2017. A cohort seat is not a Delaware address, and treating one as the other is how a Delaware short list becomes unworkable on the first phone call.

DTP@STAR opened in 2016 and now houses over twelve young companies across agriculture, life sciences, advanced materials, renewable energy, sustainable chemistry, medical devices and IT, with 41 companies having passed through and roughly 250 full-time jobs created. Its space is fully committed, which is driving construction of 6 Innovation Way, a three-story 90,000 sq ft lab building with first-phase availability in Q2 2026 where QPS Holdings is leasing about 55,515 sq ft. A fully committed incubator plus a new building under lease is the strongest activity signal in the state, because somebody underwrote it with capital.

Each input proves something different:

NIIMBL's 226 members are mostly competitors, and the fee tiers find the exceptions

NIIMBL lists 226 member organizations spanning industry, academia, government and nonprofits, and publishes a searchable organization directory. Read as a target list, it fails: the large industry names are Amgen-class biopharma and the academic names are universities, so most of the roster is acquirers and research partners rather than acquisition candidates.

The fee structure is the screen nobody uses. NIIMBL's industry membership tiers run $50K, $100K, $250K, $450K and $650K, and Tier 1 members can sponsor up to three companies of 500 or fewer employees under a Small-to-Medium Manufacturer Pass with the fee waived. That mechanism gives you two things a directory never does. It bounds headcount, since an SMM Pass holder is under 500 employees by definition. And it names a sponsor: a large member vouched for that company and paid for its seat, which is a warm path into a conversation instead of a cold email.

The institute has the money to make this worth tracking. Commerce and NIST committed $153M to NIIMBL in 2021, combining a $70M five-year renewal with $83M in pandemic-response funds and pushing total commitment past $232M in its first decade. Membership is an invoice. A tier and a sponsor are evidence.

Working Project Call 9.1 down to a biologics manufacturing short list

Run one project call end to end to see the method work. In May 2026, NIST announced that NIIMBL had funded 8 member-led projects totaling $9.7M across 39 participating organizations, concentrated on real-time process analytics, AI/ML process optimization and novel protein expression platforms. Take a mandate that reads "inline analytics and process control for biologics manufacturing, North America, bolt-on scale" and work it:

Run honestly, that intersection lands in single digits, and every name on it carries three things a directory entry cannot supply: a dated federal cost-share commitment, a headcount ceiling, and a named sponsor who already works with them. The Delaware cross-reference in step five usually returns one or two companies, which is the correct answer rather than a disappointing one. The mandate asked for a technology, and the geography was a way in.

Doing this for one institute in one state is a morning's work. Doing it across every manufacturing institute, research park and incubator your mandate touches is the job Find Startups does: you give Chibit the industry and region, and it returns companies already screened for being active and relevant to that mandate.

The sustainable chemistry and clean energy layer a biotech tag will never return

DTP@STAR's own sector list includes renewable energy, sustainable chemistry and advanced materials alongside life sciences, and that overlap is where a sector-tagged query loses companies. A startup doing enzymatic catalysis, bioprocess separations or bio-based monomers gets classified under chemicals or industrials, so it never appears in a biotech-filtered list even though its unit operations are the ones a biologics manufacturer cares about. Delaware's industrial history makes this layer unusually thick: the state's economic development office names Bloom Energy, Chemours' $150M Discovery Hub and ILC Dover among STAR's occupants, and those anchors seed spinouts and hire from the same labs.

The anchors themselves are not purchasable, which is the standard mistake with campus recruitment copy. Chemours will not sell you its R&D hub. The anchors give you a reason to believe the small layer underneath them has real process engineering talent. Delaware Bio reports the state's life sciences sector employs about 11,000 people, generates at least $2B in GDP annually, and has seen a 65% increase in new biotech R&D company formations over the past decade. Screen on the unit operation, not the sector tag, and that formation growth becomes visible.

Which roster to open first

If your mandate names biopharma manufacturing technology, start with NIIMBL's most recent project call and the SMM Pass population, then score what survives. The scoring step matters more here than usual, because a project participant can be active and still irrelevant to you, which is the distinction our relevance, activity and fit scoring post works through.

If you do not yet have a mandate written down, write it before you open any roster. A one-page mandate turns the STAR directory from an interesting list into a filter, and the one-page M&A sourcing mandate format is the version we use.

If you already have the STAR Resident Directory open and are treating it as a pipeline, stop and sort it. It mixes UD colleges, a physical therapy clinic, a Fortune 500 R&D hub and two-person incubator tenants as equal entries. We worked through that same failure mode for UConn Tech Park's two acquirable layers and across the four distinct pools at Nebraska Innovation Campus.

If your mandate is therapeutics rather than manufacturing, Delaware is thin and you should say so internally. The 41 companies that have passed through DTP@STAR produced roughly 250 jobs between them, about six employees each. That is a bolt-on and licensing layer, not a platform-deal layer. About 45 miles up the corridor, Philadelphia's cell and gene therapy cluster around uCity Square holds the therapeutics depth Newark does not.

FAQ about sourcing Delaware biotech startups

Are NIIMBL's 226 members Delaware companies?

Most NIIMBL members are not Delaware companies. The institute is headquartered on the STAR Campus in Newark, but its membership is national and international, dominated by large biopharma manufacturers and universities. The member directory is useful as a technology screen and a warm-introduction map, not as a Delaware company list.

Is The Innovation Space on the STAR Campus?

The Innovation Space is not on the STAR Campus. It operates at the former DuPont Experimental Station in Wilmington, roughly 13 miles from Newark, while NIIMBL and the DTP@STAR incubator are both on STAR. Any Delaware short list that treats them as one site will send your team to the wrong building.

How do I strip Delaware incorporation noise out of a target list?

Delaware incorporation noise comes out by requiring a verified operating address rather than a state field. Ask for a lab or plant address, a local phone number, and a named person who works in the state, then check that address against the STAR Resident Directory, the DTP@STAR tenant list or a Science Inc. cohort page. A registered agent address in Wilmington shared across thousands of filings fails all three tests.

Which Delaware biotech startups have reached acquirable scale?

A handful of Delaware biotechs have grown past startup scale, and the publicly traded ones are comparables rather than targets. Prelude Therapeutics is public, so it belongs in the valuation-reference column. Uvax Bio, which technical.ly reports came out of Scripps Research and chose Delaware, is the shape of company worth tracking: a venture-backed spinout with a real local footprint rather than a registry entry.

How often do the STAR and DTP@STAR rosters change?

Tenant rosters at STAR and DTP@STAR change slowly, on lease cycles, so a quarterly re-check is enough. Three events should trigger an immediate re-check: a new NIIMBL project call announcement, a Science Inc. cohort announcement, and the Q2 2026 first-phase opening at 6 Innovation Way, each of which moves a batch of companies at once.

Teams with a biopharma manufacturing mandate get the most out of Delaware by going in the right order: the latest project call, then the fee tier, then the street address. Open Find Startups with that mandate written down, and Chibit returns companies screened as active and relevant to your industry and region, already past the registry test and short enough to act on.